Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dme.14053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome.
Diabetes Obes Metab
November 2023
Department of Endocrinology, Lipscomb University, Nashville, Tennessee, USA.
Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also by improving beta cell function. Because of the improved beta cell function the glycaemic control that occurs with pioglitazone is prolonged. Pioglitazone has positive effects not only on cardiac risk factors and surrogate measures of cardiovascular disease, it also lowers the incidence of cardiac events in patients with diabetes.
View Article and Find Full Text PDFEvaluation of Sida cordifolia and Sida rhombifolia extracts in a rat model of streptozotocin-induced diabetic nephropathy.
Polim Med
June 2023
Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard University, New Delhi, India.
Background: Sida cordifolia and Sida rhombifolia are regarded as useful herbs as they have been shown to be effective, inexpensive and harmless in the prevention of diabetes, and are recognized as valuable therapeutic substances.
Objectives: The purpose of this study was to assess the effect of S. cordifolia and S.
Effects of Cardiac Sympathetic Neurodegeneration and PPAR Activation on Rhesus Macaque Whole Blood miRNA and mRNA Expression Profiles.
Biomed Res Int
February 2021
Preclinical Parkinson's Research Program, Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, 53706 WI, USA.
Degeneration of sympathetic innervation of the heart occurs in numerous diseases, including diabetes, idiopathic REM sleep disorder, and Parkinson's disease (PD). In PD, cardiac sympathetic denervation occurs in 80-90% of patients and can begin before the onset of motor symptoms. Today, there are no disease-modifying therapies for cardiac sympathetic neurodegeneration, and biomarkers are limited to radioimaging techniques.
View Article and Find Full Text PDFTreatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.
Eur J Gastroenterol Hepatol
May 2019
Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and is becoming the most frequent indication of liver transplantation. Cardiovascular disease is the main cause of death in these patients. There is no Food and Drug Association-approved medication for NAFLD patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!